Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib versus methotrexate in DMARD-naive rheumatoid arthritis
ChiCTR2100048185Phase 4Completed
- Sponsor
- Peking University First Hospital
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of tofacitinib in rheumatoid arthritis (RA) (2 arms), sponsored by Peking University First Hospital. Primary endpoint: Clinical target achievement rate at week 12. Started Jul 2021; status: completed.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on ChiCTR2100048185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100048185.